ArticleJournal of substance abuse treatment2021
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
Article in Journal of substance abuse treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review.The International journal on drug policy · 2024Pooled it
- Understanding the Impacts of Novel Coronavirus Outbreaks on People Who Use Drugs: A Systematic Review to Inform Practice and Drug Policy Responses to COVID-19.International journal of environmental research and public health · 2021Pooled it
- Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.Addiction science & clinical practice · 2023Trial
- The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services.Harm reduction journal · 2021Trial
- Envisioning a Humane and Accessible US Methadone Treatment System: Generating Policy and Practice Recommendations From the Liberate Methadone Movement.Substance use & addiction journal · 2026Article
- Clinical outcomes from a mid-western opioid treatment program during covid-19 emergency regulations: a brief report on the effect of tetrahydrocannabinol (THC) use on take home methadone access.Harm reduction journal · 2026Article
- Acceptability of and Implementation Supports for Video Directly Observed Treatment to Enhance Methadone Dosing Flexibility in a Multisite Opioid Treatment Program: Qualitative Rapid Needs Assessment Study.JMIR formative research · 2026Article
- Developing and validating measures of take-home methadone with administrative data.Journal of substance use and addiction treatment · 2026Article
- Narrative Review of Opioid Use Disorder Treatment Changes During the COVID-19 Pandemic and Their Impact on American Indian/Alaska Native Communities.Nursing open · 2026Review
- Methadone-involved overdose deaths in urban and rural communities before and after the public health emergency flexibilities for methadone take-home doses.Drug and alcohol dependence reports · 2025Article
- State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset.Addiction (Abingdon, England) · 2025Article
- Article
- "I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.Journal of substance use and addiction treatment · 2025Article
- Community-Driven Research with People Who Use Drugs: A Virtual Project During Multiple Epidemics.Sociological methodology · 2025Article
- State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States.Substance use & misuse · 2025Article
- "Tethered to this ball and chain": Women's perspectives on bodily agency within opioid treatment programs.The International journal on drug policy · 2024Article
- Methadone clinic staff perceptions of trauma-informed and patient-centered care: the role of individual staff characteristics.Addiction science & clinical practice · 2024Article
- Methadone treatment utilization and overdose trends among Medicaid beneficiaries in New Jersey before and during the COVID-19 pandemic.Journal of substance use and addiction treatment · 2024Article
- "If it wasn't for them, I don't think I would be here": experiences of the first year of a safer supply program during the dual public health emergencies of COVID-19 and the drug toxicity crisis.Harm reduction journal · 2024Article
- Impact of the COVID-19 Pandemic on HIV Test Uptake Among People Who Inject Drugs in the Context of an HIV Outbreak.AIDS and behavior · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMethadone maintenance treatment is a life-saving treatment for people with opioid use disorders (OUD). The coronavirus pandemic (COVID-19) has introduced many concerns surrounding access to opioid treatment. In March 2020, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued guidance allowing for the expansion of take-home methadone doses. We sought to describe changes to treatment experiences from the perspective of persons receiving methadone at outpatient treatment facilities for OUD.
methodsWe conducted an in-person survey among 104 persons receiving methadone from three clinics in central North Carolina in June and July 2020. Surveys collected information on demographic characteristics, methadone treatment history, and experiences with take-home methadone doses in the context of COVID-19 (i.e., before and since March 2020).
resultsBefore COVID-19, the clinic-level percent of participants receiving any amount of days' supply of take-home doses at each clinic ranged from 56% to 82%, while it ranged from 78% to 100% since COVID-19. The clinic-level percent of participants receiving a take-homes days' supply of a week or longer (i.e., ≥6 days) since COVID-19 ranged from 11% to 56%. Among 87 participants who received take-homes since COVID-19, only four reported selling their take-home doses.
conclusionsOur study found variation in experiences of take-home dosing by clinic and little diversion of take-home doses. While SAMSHA guidance should allow expanded access to take-home doses, adoption of these guidelines may vary at the clinic level. The adoption of these policies should be explored further, particularly in the context of benefits to patients seeking OUD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.